Galal, S., Raafat, N. (2016). Monocyte Chemoattractant Protein-1 as a Diagnostic Marker for Detection of Hepatocellular Carcinoma in Egypt. Afro-Egyptian Journal of Infectious and Endemic Diseases, 6(2), 75-81. doi: 10.21608/aeji.2016.9670
Sherif M Galal; Nermin Raafat. "Monocyte Chemoattractant Protein-1 as a Diagnostic Marker for Detection of Hepatocellular Carcinoma in Egypt". Afro-Egyptian Journal of Infectious and Endemic Diseases, 6, 2, 2016, 75-81. doi: 10.21608/aeji.2016.9670
Galal, S., Raafat, N. (2016). 'Monocyte Chemoattractant Protein-1 as a Diagnostic Marker for Detection of Hepatocellular Carcinoma in Egypt', Afro-Egyptian Journal of Infectious and Endemic Diseases, 6(2), pp. 75-81. doi: 10.21608/aeji.2016.9670
Galal, S., Raafat, N. Monocyte Chemoattractant Protein-1 as a Diagnostic Marker for Detection of Hepatocellular Carcinoma in Egypt. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2016; 6(2): 75-81. doi: 10.21608/aeji.2016.9670
Monocyte Chemoattractant Protein-1 as a Diagnostic Marker for Detection of Hepatocellular Carcinoma in Egypt
1Departments of Tropical Medicine, Faculty of Medicine, Zagazig University, Egypt
2Departments of Medical Biochemistry, Faculty of Medicine, Zagazig University, Egypt.
Abstract
Background and study aim: Hepatocellullar carcinoma (HCC) is usually diagnosed at advanced stage resulting in limited therapeutic options and poor prognosis. The role of alpha-fetoprotein (AFP) in the diagnosis of HCC is controversial. Here, we investigated the role of Monocyte Chemoattractant Protein -1 (MCP-1), a serum biomarker, alone or in combination with AFP for detection of HCC. Patients and Methods: 116 patients with liver cirrhosis were included. The patients were divided into 2 groups: HCC group included 58 patients with HCC and non-HCC patients as a control group included 58 patients with no evidence of hepatic focal masses. Routine laboratory investigations, AFP, MCP-1, pelvi-abdominal ultrasonography (US) and triphasic computed tomography (CT) scan were performed in all patients. Results: It was found that MCP-1 at a cut-off value >0.390 ng/ml has a sensitivity of 75.8% and specificity of 88.3% with AUROC 0.916; But AFP at a cut-off value >20 ng/ml has a sensitivity of 86.5% and specificity of 96.4% with AUROC 0.924, while combined (AFP+ MCP-1) at a cut-off value >23.390 ng/ml has a higher sensitivity (96.5%) specificity of 100% with AUROC 0.995. Conclusion: Monocyte Chemoattractant Protein-1 (MCP-1) can be identified as an adjuvant biomarker for HCC detection. Combined (AFP+MCP-1) showed higher diagnostic ability than MCP-1 alone or AFP alone in HCC detection.